| Literature DB >> 31510971 |
Chang-Wang Wang1, Min Ma2, Wei-Guang Lu1, Ru-Qin Luo3.
Abstract
BACKGROUND: Prodynorphin (PDYN) gene polymorphisms have been linked with opioid dependence (OD) with conflicting outcomes, the aim of this study is to synthesize the existing evidence of the association between PDYN polymorphisms and OD susceptibility.Entities:
Keywords: Meta-analysis; Opioid dependence; Polymorphism; Prodynorphin
Year: 2019 PMID: 31510971 PMCID: PMC6737717 DOI: 10.1186/s12888-019-2272-7
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1Flow chart of literature search and screen
Characteristics of included studies
| Study | Year | Country | Ethnicity | Gender | Sample size | OD (%) | Control (%) | HWE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | W | MM | MW | WW | M | W | MM | MW | WW | |||||||
|
| ||||||||||||||||
| Yuanyuan et al. | 2018 | China | Asian | Both | 541/566 | 14.3 | 85.7 | 22.2 | 24.2 | 73.6 | 13.2 | 86.8 | 1.6 | 23.1 | 75.3 | 0.77 |
| Nagaya et al. | 2018 | Malaysia | Asian | Male | 459/543 | 16.1 | 83.9 | 34.9 | 25.3 | 71.2 | 12.4 | 87.6 | 2.4 | 20.1 | 77.5 | 0.07 |
| Hashemi et al. | 2018 | Iran | Asian | Both | 216/219 | 43.1 | 56.9 | 19.9 | 46.3 | 33.8 | 30.1 | 69.9 | 3.2 | 53.9 | 52.9 | <0.01 |
| Clarke et al. I | 2012 | USA | Caucasian | Both | 1030/644 | 25.0 | 75.0 | 6.0 | 38.0 | 56.0 | 27.6 | 72.4 | 8.9 | 37.6 | 53.6 | 0.12 |
| Clarke et al. II | 2012 | USA | African | Both | 330/663 | 46.8 | 53.2 | 23.0 | 47.6 | 29.4 | 48.2 | 51.8 | 22.8 | 50.8 | 26.4 | 0.64 |
| Wei et al. | 2011 | China | Asian | Both | 304/301 | 21.9 | 78.1 | 4.9 | 33.9 | 61.2 | 15.3 | 84.7 | 1.3 | 27.9 | 70.8 | 0.18 |
| Jia et al. | 2010 | China | Asian | Both | 212/200 | 23.6 | 76.4 | 3.3 | 40.6 | 56.1 | 25.7 | 74.3 | 4.5 | 42.5 | 53.0 | 0.12 |
|
| ||||||||||||||||
| Yuanyuan et al. | 2018 | China | Asian | Both | 541/566 | 16.4 | 83.6 | 2.0 | 28.7 | 69.3 | 15.5 | 84.5 | 1.9 | 27.0 | 71.0 | 0.42 |
| Nagaya et al. | 2018 | Malaysia | Asian | Male | 459/543 | 48.2 | 51.8 | 22.7 | 51.2 | 23.1 | 50.9 | 49.1 | 26.0 | 49.9 | 24.1 | 0.97 |
| Clarke et al. I | 2012 | USA | Caucasian | Both | 1037/652 | 35.0 | 65.0 | 11.7 | 46.6 | 41.8 | 37.9 | 62.1 | 15.3 | 45.1 | 39.6 | 0.28 |
| Clarke et al. II | 2012 | USA | African | Both | 336/668 | 28.3 | 71.7 | 8.6 | 39.3 | 52.1 | 25.1 | 74.9 | 6.3 | 37.6 | 56.1 | 1.00 |
| Clarke et al. | 2009 | China | Asian | Female | 119/176 | 19.3 | 80.7 | 3.4 | 31.9 | 64.7 | 11.4 | 88.6 | 0.6 | 21.6 | 77.8 | 0.34 |
|
| ||||||||||||||||
| Nagaya et al. | 2018 | Malaysia | Asian | Male | 459/543 | 17.9 | 82.1 | 3.9 | 27.9 | 68.2 | 17.6 | 82.4 | 3.3 | 28.6 | 68.1 | 0.72 |
| Clarke et al. I | 2012 | USA | Caucasian | Both | 948/644 | 13.5 | 86.5 | 14.8 | 24.1 | 74.5 | 17.0 | 83.0 | 1.9 | 30.3 | 67.9 | 0.06 |
| Clarke et al. II | 2012 | USA | African | Both | 336/660 | 21.6 | 78.4 | 5.1 | 33.0 | 61.9 | 18.9 | 81.1 | 3.0 | 31.8 | 65.2 | 0.35 |
| Wei et al. | 2011 | China | Asian | Both | 304/300 | 16.3 | 83.7 | 3.9 | 24.7 | 71.4 | 17.0 | 83.0 | 0.7 | 32.7 | 66.7 | <0.01 |
| Jia et al. | 2010 | China | Asian | Both | 212/90 | 19.1 | 80.9 | 4.7 | 28.8 | 66.5 | 42.8 | 57.2 | 6.7 | 72.1 | 21.1 | <0.01 |
| Clarke et al. | 2009 | China | Asian | Female | 119/163 | 17.6 | 82.4 | 5.9 | 23.5 | 70.6 | 13.8 | 86.2 | 0 | 27.6 | 72.4 | 0.04 |
|
| ||||||||||||||||
| Yuanyuan et al. | 2018 | China | Asian | Both | 541/566 | 15.2 | 84.8 | 2.4 | 25.5 | 72.1 | 13.5 | 86.5 | 19.4 | 23.1 | 74.9 | 0.81 |
| Hashemi et al. | 2018 | Iran | Asian | Both | 216/219 | 38.2 | 61.8 | 7.9 | 60.6 | 31.5 | 37.2 | 62.8 | 4.1 | 66.2 | 29.7 | <0.01 |
| Wei et al. | 2011 | China | Asian | Both | 304/300 | 21.9 | 78.1 | 5.3 | 33.2 | 61.5 | 15.3 | 84.7 | 1 | 28.7 | 70.3 | 0.07 |
| Jia et al. | 2010 | China | Asian | Both | 212/200 | 18.6 | 81.4 | 4.7 | 27.8 | 67.5 | 27.3 | 72.8 | 14 | 26.5 | 59.5 | <0.01 |
OD opioid dependence, M mutant allele, W wild allele, HWE Hardy-Weinberg Equilibrium
Quality of included studies
| Item/Study | Nagaya et al. 2018 [ | Hashemi et al. 2018 [ | Clarke et al. 2012 [ | Wei et al. 2011 [ | Jia et al. | Clarke et al. 2009 [ | Yuanyuan et al. 2018 [ |
|---|---|---|---|---|---|---|---|
| Adequate definition of cases | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
| Representativeness of cases | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ |
| Selection of control subjects | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ |
| Definition of control subjects | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
| Control for important factor or additional factor | ★☆ | ★☆ | ★☆ | ★☆ | ☆☆ | ☆☆ | ★☆ |
| Exposure assessment | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
| Same method of ascertainment for all subjects | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
| Non-response rate | ★ | ★ | ★ | ★ | ★ | ★ | ★ |
★, a star given; ☆, a star not given
Association between prodynorphin gene polymorphisms and opioid dependence
| Genetic model | Association | FDR | Effect model | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | ||||||
|
| |||||||
| Overall | |||||||
| A vs. G | 1.16 | 0.94–1.41 | 0.16 | 0.28 | R | 81 | <0.01 |
| AA vs. GG | 1.53 | 0.83–2.84 | 0.17 | 0.28 | R | 84 | <0.01 |
| AG vs. GG | 1.06 | 0.95–1.19 | 0.32 | 0.32 | F | 32 | 0.18 |
| AA + AG vs. GG | 1.12 | 0.93–1.34 | 0.24 | 0.30 | R | 63 | 0.01 |
| AA vs. AG + GG | 1.52 | 0.85–2.70 | 0.16 | 0.28 | R | 83 | <0.01 |
| Asian | |||||||
| A vs. G | 1.30 | 1.04–1.62 | 0.02 | 0.05 | R | 70 | 0.01 |
| AA vs. GG | 2.21 | 0.96–5.09 | 0.06 | 0.07 | R | 76 | <0.01 |
| AG vs. GG | 1.17 | 1.01–1.36 | 0.04 | 0.07 | F | 7 | 0.37 |
| AA + AG vs. GG | 1.25 | 1.04–1.51 | 0.02 | 0.05 | F | 40 | 0.15 |
| AA vs. AG + GG | 2.13 | 0.94–4.83 | 0.07 | 0.07 | R | 76 | <0.01 |
|
| |||||||
| Overall | |||||||
| G vs. A | 1.02 | 0.85–1.22 | 0.87 | 0.94 | R | 72 | 0.01 |
| GG vs. AA | 0.98 | 0.68–1.43 | 0.94 | 0.94 | R | 58 | 0.05 |
| GA vs. AA | 1.06 | 0.94–1.20 | 0.36 | 0.94 | F | 20 | 0.29 |
| GG + GA vs. AA | 1.07 | 0.89–1.30 | 0.46 | 0.94 | R | 55 | 0.06 |
| GG vs. GA + AA | 0.95 | 0.69–1.31 | 0.77 | 0.94 | R | 52 | 0.08 |
| Asian | |||||||
| G vs. A | 1.06 | 0.76–1.46 | 0.74 | 0.74 | R | 78 | 0.01 |
| GG vs. AA | 0.90 | 0.65–1.23 | 0.50 | 0.63 | F | 49 | 0.14 |
| GA vs. AA | 1.10 | 0.91–1.32 | 0.34 | 0.63 | R | 51 | 0.13 |
| GG + GA vs. AA | 1.16 | 0.82–1.63 | 0.41 | 0.63 | R | 68 | 0.04 |
| GG vs. GA + AA | 0.89 | 0.68–1.17 | 0.41 | 0.63 | F | 39 | 0.20 |
|
| |||||||
| Overall | |||||||
| C vs. T | 0.85 | 0.62–1.17 | 0.32 | 0.40 | R | 88 | <0.01 |
| CC vs. TT | 1.29 | 0.57–2.89 | 0.54 | 0.54 | R | 75 | <0.01 |
| CT vs. TT | 0.66 | 0.44–1.00 | 0.05 | 0.25 | R | 89 | <0.01 |
| CC + CT vs. TT | 0.71 | 0.47–1.07 | 0.11 | 0.28 | R | 89 | <0.01 |
| CC vs. CT + TT | 1.45 | 0.79–2.65 | 0.23 | 0.38 | R | 57 | 0.04 |
| Asian | |||||||
| C vs. T | 0.80 | 0.47–1.37 | 0.42 | 0.50 | R | 91 | <0.01 |
| CC vs. TT | 1.71 | 0.36–8.07 | 0.50 | 0.50 | R | 83 | <0.01 |
| CT vs. TT | 0.54 | 0.26–1.13 | 0.10 | 0.35 | R | 92 | <0.01 |
| CC + CT vs. TT | 0.60 | 0.29–1.25 | 0.17 | 0.35 | R | 93 | <0.01 |
| CC vs. CT + TT | 2. 04 | 0.66–6.27 | 0.21 | 0.35 | R | 69 | 0.02 |
|
| |||||||
| T vs. C | 1.04 | 0.74–1.46 | 0.83 | 0.83 | R | 83 | <0.01 |
| TT vs. CC | 1.34 | 0.42–4.25 | 0.62 | 0.83 | R | 85 | <0.01 |
| TC vs. CC | 1.09 | 0.92–1.30 | 0.32 | 0.83 | F | 2 | 0.38 |
| TT + TC vs. CC | 1.05 | 0.78–1.41 | 0.75 | 0.83 | R | 64 | 0.02 |
| TT vs. TC + CC | 1.34 | 0.43–4.16 | 0.61 | 0.83 | R | 85 | <0.01 |
SNP single nucleotide polymorphism, OR odds ratio, CI confidence interval, F fix-effect model, R random-effect model, FDR adjusted P-value for false discovery rate